June 2020. Volume 16. Number 2

Omalizumab is a treatment option for children with severe atopic dermatitis who do not respond to other treatments

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of Omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020;174:29-37.

Reviewers: Aparicio Rodrigo M1, Albi Rodríguez MS2.
1Pediatra. CS Entrevías. Profesor asociado. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. España.
2Servicio de Neumología y Alergia Infantil. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: María Aparicio Rodrigo. Email: maparicio@salud.madrid.org
Reception date: 13/02/2020
Acceptance date: 09/03/2020
Publication date: 08/04/2020

Abstract

Authors’ conclusions: omalizumab significantly reduced atopic dermatitis severity and improved quality of life in a pediatric population with atopy and severe eczema despite highly elevated total IgE levels at baseline. The result was associated with a potent topical corticosteroid sparing effect and may suggest that omalizumab is a treatment option for difficult-to-manage severe eczema in children with atopy.

Reviewers’ commentary: omalizumab is a treatment option for children over 6 years of age with severe atopic dermatitis and high IgE levels who do not respond to other treatments. The response to the treatment is moderate, allows for a reduction in the use of high-potency topical steroids, is maintained throughout the duration of the treatment and decreases in the weeks following the end of the treatment.

How to cite this article

Aparicio Rodrigo M, Albi Rodríguez MS. Omalizumab es una opción terapéutica en niños con dermatitis atópica grave resistente a otros tratamientos. Evid Pediatr. 2020;16:19.

AVC | Critically appraised articles

Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of Omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020;174:29-37.

Reviewers: Aparicio Rodrigo M1, Albi Rodríguez MS2.
1Pediatra. CS Entrevías. Profesor asociado. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. España.
2Servicio de Neumología y Alergia Infantil. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: María Aparicio Rodrigo. Email: maparicio@salud.madrid.org
Reception date: 13/02/2020
Acceptance date: 09/03/2020
Publication date: 08/04/2020

How to cite this article

Aparicio Rodrigo M, Albi Rodríguez MS. Omalizumab es una opción terapéutica en niños con dermatitis atópica grave resistente a otros tratamientos. Evid Pediatr. 2020;16:19.

08/04/2020

Linked Comment